| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/28/2013 | US20130053436 Compounds, compositions and methods |
| 02/28/2013 | US20130053414 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 02/28/2013 | US20130053368 Methods for treatment of parkinson's disease |
| 02/28/2013 | US20130052149 Process for treating and/or forming a non-newtonian fluid using microchannel process technology |
| 02/28/2013 | CA2844809A1 Combination cancer therapy of hsp90 inhibitor with antimetabolite |
| 02/27/2013 | EP2562172A1 Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses |
| 02/27/2013 | EP2561887A2 Cancer therapy sensitizer |
| 02/27/2013 | EP2561874A2 Pharmaceutical compositions for treating cancer |
| 02/27/2013 | EP2561868A1 Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| 02/27/2013 | EP2560666A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate) |
| 02/27/2013 | EP2560665A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates |
| 02/27/2013 | EP2560659A2 Compositions and method for the treatment of multiple myeloma |
| 02/27/2013 | EP2560658A2 Methods of enhancing antibody-dependent cellular cytotoxicity |
| 02/27/2013 | EP2560657A2 Anti-viral compounds |
| 02/27/2013 | EP2560646A2 Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain |
| 02/27/2013 | EP2560641A2 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| 02/27/2013 | EP2560632A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them |
| 02/27/2013 | EP2560631A2 Baclofen and acamprosate based therapy of neurogical disorders |
| 02/27/2013 | EP2560630A2 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment |
| 02/27/2013 | EP2560629A2 Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| 02/27/2013 | EP2560605A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates) |
| 02/27/2013 | EP2560486A1 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| 02/27/2013 | EP2143444A9 Compositions for inhibition of angiogenesis |
| 02/27/2013 | CN102947446A Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma |
| 02/27/2013 | CN102943108A Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| 02/27/2013 | CN102940891A Lipids, lipid complexes and use thereof |
| 02/27/2013 | CN102940886A Biological barrier penetrating agent and preparation method thereof |
| 02/27/2013 | CN102940884A Inhibitor for hepatoma carcinoma cell and application to aspect of inhibiting tumor growth thereof |
| 02/27/2013 | CN102940638A Administration of dipeptidyl peptidase inhibitors |
| 02/27/2013 | CN101959532B Pharmaceutical composition for transnasal administration |
| 02/27/2013 | CN101883589B Pharmaceutical compositon for cleansing of the bowel |
| 02/27/2013 | CN101010102B Composition comprising non-oxidizable fatty acid analogoues and plant and/or fish oils |
| 02/26/2013 | US8383775 Cytokine zalpha11 ligand |
| 02/26/2013 | US8383769 Peptides for inhibiting chemokine binding to chemokine receptors |
| 02/26/2013 | US8383767 Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
| 02/26/2013 | US8383665 Immunomodulatory compositions |
| 02/26/2013 | US8383626 Nitric oxide donors for inducing neurogenesis |
| 02/26/2013 | US8383613 Methods for the treatment of cancer |
| 02/26/2013 | US8383158 Methods and compositions to treat myocardial conditions |
| 02/26/2013 | US8383126 Bacterial pheromones and uses thereof |
| 02/26/2013 | US8383110 Modulators of Candida hyphal morphogenesis and uses thereof |
| 02/26/2013 | US8383084 Modify surface of spore to increase adherence to phagocyte; activate phagocytic cells; ingest spore with phagocyte; killing spore by blocking spore-induced phagocyte cell death; increase activation, production of antimicrobial and cytocidal agents endogenous nitric oxide, inflammatory cytokines |
| 02/26/2013 | CA2564546C Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/26/2013 | CA2551780C The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| 02/26/2013 | CA2550848C Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 02/26/2013 | CA2532730C Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/26/2013 | CA2492068C Assays for assembly of ebola virus nucleocapsids |
| 02/26/2013 | CA2389644C A novel polypeptide hormone phosphatonin |
| 02/21/2013 | WO2013024164A1 Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| 02/21/2013 | WO2013024067A1 Use of antioxidants for improving animal health |
| 02/21/2013 | CA2845039A1 Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| 02/20/2013 | EP2559434A2 Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| 02/20/2013 | EP2558866A1 Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| 02/20/2013 | EP2558502A1 Tumor cell-derived microvesicles |
| 02/20/2013 | EP2558126A2 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| 02/20/2013 | EP2558124A1 Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| 02/20/2013 | EP2558122A1 Combination treatment with vegf-c antagonists |
| 02/20/2013 | EP2558109A2 Method for treating solid tumors |
| 02/20/2013 | EP2558108A1 Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
| 02/20/2013 | EP2558106A1 Methods and compositions for improving implant osseointegration |
| 02/20/2013 | EP2558101A1 Topical treatments for pain |
| 02/20/2013 | EP2558098A2 Treatment of endocrine resistant breast cancer |
| 02/20/2013 | EP2558097A1 Compound for treatment of respiratory condition or disease |
| 02/20/2013 | EP2558096A1 Combination of hypoxia-inducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors |
| 02/20/2013 | EP2558092A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| 02/20/2013 | EP2558084A2 Combination of vitamin k and nicotinamide |
| 02/20/2013 | EP2557923A1 Treatment of cancers having k-ras mutations |
| 02/20/2013 | EP2557921A1 Methods for treatment of sleep-related breathing disorders |
| 02/20/2013 | CN202740434U Plaster patch |
| 02/20/2013 | CN102939082A Metal entrapped bioactive composites |
| 02/20/2013 | CN102939057A Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull |
| 02/20/2013 | CN102935231A Treatments using citrulline |
| 02/20/2013 | CN102935230A Use of RNAi inhibiting PARP activtiy for the manufacture of a medicament for the treatment of cancer |
| 02/20/2013 | CN102935229A New medical application of metallic simple substances |
| 02/20/2013 | CN102935228A Reagent for tumor treatment, its use and method |
| 02/20/2013 | CN102935081A Dipeptidyl peptidase inhibitors for treating diabetis |
| 02/20/2013 | CN102309758B Medicinal composition for treating diseases caused by enterovirus infections |
| 02/20/2013 | CN102294031B Pharmaceutical formulation comprising proton pump inhibitor, NSAID and antacids |
| 02/20/2013 | CN102274513B Tumor growth inhibited by ERK1/2 inhibitor through stimulating expression of macrophage interferon gamma |
| 02/20/2013 | CN102046164B Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders |
| 02/20/2013 | CN102038952B Composition for improving the viability of nerve cells and use of the composition |
| 02/19/2013 | USRE44022 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators |
| 02/19/2013 | US8377959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 02/19/2013 | US8377936 Nicotinic receptor agonists for the treatment of inflammatory diseases |
| 02/19/2013 | US8377912 Preparation for the prevention and/or treatment of vascular disorders |
| 02/19/2013 | US8377904 preventing cartilage degradation in animals, using a combination of a sulfur containing amino acid and manganese |
| 02/19/2013 | US8377878 Therapies for chronic renal failure |
| 02/19/2013 | US8377692 Process for the manufacturing of human mononuclear phagocytic leukocytes |
| 02/19/2013 | US8377679 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 02/19/2013 | US8377424 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents; treatment of gingivitis |
| 02/19/2013 | CA2467930C Treatment of pml targeting jc virus agno |
| 02/19/2013 | CA2448382C Use of hepcidin as a regulator of iron homeostasis |
| 02/19/2013 | CA2372947C Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 02/19/2013 | CA2276450C A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 02/14/2013 | WO2013022091A1 Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| 02/14/2013 | US20130041137 von Willebrand Factor (vWF) - Cleaving Protease |
| 02/14/2013 | DE102011052687A1 Verwendung von Antioxidantien The use of antioxidants |
| 02/13/2013 | EP2557159A1 Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma |
| 02/13/2013 | EP2557155A1 Metal salen complex derivative and process for production thereof |
| 02/13/2013 | EP2555801A1 Selection and use of host cells for production of glycoproteins |